Bird & Bird advises Genetic Signatures Limited on its successful placement and rights issue raising AUD$16 million

Bird & Bird is pleased to have advised Genetic Signatures Limited, an Australian Securities Exchange listed and Australian-based global molecular diagnostics company, on its successful placement and rights issue to raise approximately AUD$16 million (“Capital Raise”).

The Capital Raise was constituted by an AUD$8 million institutional placement and a fully underwritten AUD$8 million pro-rata non-renounceable rights issue to existing shareholders.

Proceeds from the Capital Raise will be used to fund growth initiatives including US regulatory clearances, US product launches, new instrument development and working capital.

Bird & Bird's team was led by Corporate partner Chris Clarke supported by associate Carl Ritchie.

Chris Clarke comments: “We were delighted to assist Genetic Signatures on this important capital raising, which proves that good businesses can still attract funding notwithstanding difficult capital markets.”  


News & Deals

More News & Deals

News

Bird & Bird ATMD LLP advised Qapita Fintech Pte. Ltd. in its US$17.22 million fundraising round

Mar 01 2024

Read More

News

Bird & Bird ATMD LLP advised Qapita Fintech Pte. Ltd. in its US$17.22 million fundraising round

Mar 01 2024

Read More

Deal

Bird & Bird advises Evli Growth Partners

Mar 01 2024

Read More

News

Bird & Bird succeeded in first substantive patent litigation appeal case at UPC Court of Appeal for NanoString

Feb 27 2024

Read More

Deal

Bird & Bird advised Orosur Mining Inc. on their recent fundraising for its exploration projects in South America and Africa

Feb 27 2024

Read More

Deal

Bird & Bird advised Greenerwave, a pioneering French deep-tech on its €15 million Series A financing round

Feb 13 2024

Read More